The IGF system in patients with inflammatory bowel disease treated with prednisolone or infliximab: potential role of the stanniocalcin-2/PAPP-A/IGFBP-4 axis
Anyone promising instant results is either lying or selling contaminated compounds possibly both at the same time
Well - it's been a very strange journey
This approach is best suited to: Adults 4065 with longevity-focused health goals who are already engaged in foundational health optimisation (sleep, nutrition, resistance training, metabolic health) Individuals with confirmed age-related decline in GH/IGF-1, with symptoms including reduced lean mass, increased visceral fat, impaired recovery, or sleep-quality deterioration Patients with chronically elevated inflammatory markers without acute disease Adults with disrupted circadian rhythm or age-related sleep degradation (Epitalon specifically addresses this) Those who have optimised foundational lifestyle variables and want an additional, evidence-informed intervention layer It is not appropriate as a standalone intervention for adults who have not addressed metabolic health, sleep, or body composition fundamentals
Mammalian Sirt1: insights on its biological functions
Therefore, using an ester-linked analog will not recapitulate the unique signaling and membrane-modulating properties of the ether lipid class
